SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 12, 2006
AXONYX INC.
(Exact name of Registrant as Specified in its Charter)
|
|
|
|
|
|
|
|
|
|
Nevada |
|
000-25571 |
|
86-0883978 |
|
|
|
|
|
|
|
|
|
|
|
(State or Other Jurisdiction |
|
(Commission file Number) |
|
(IRS Employer |
|
|
|
of Incorporation) |
|
|
|
Identification No.) |
|
|
|
|
|
|
|
|
500 Seventh Avenue, 10th Floor, New York, New York 10018 |
|
|
|
|
|||
|
|
(Address of Principal Executive Offices) |
(Zip Code) |
|
Registrant’s telephone number, including area code (212) 645-7704
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
x |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-2 under the Exchange Act (17 CFR 240.14a-2) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On June 12, 2006, the slide presentation attached hereto as Exhibit 99.1 will be presented by TorreyPines Therapeutics, Inc. at the Pacific Growth Equities Life Sciences Growth Conference.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 12th day of June, 2006.
|
|
|
|
|
|
|
AXONYX INC. |
||
|
|
|
||
|
|
By: |
/s/ S. Colin Neill |
|
|
|
|
|
|
|
|
Name: |
S. Colin Neill |
|
|
|
Title: |
Chief Financial Officer |
|
3